These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 24080461)
1. Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Turlington M; Chun A; Tomar S; Eggler A; Grum-Tokars V; Jacobs J; Daniels JS; Dawson E; Saldanha A; Chase P; Baez-Santos YM; Lindsley CW; Hodder P; Mesecar AD; Stauffer SR Bioorg Med Chem Lett; 2013 Nov; 23(22):6172-7. PubMed ID: 24080461 [TBL] [Abstract][Full Text] [Related]
2. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. Jacobs J; Grum-Tokars V; Zhou Y; Turlington M; Saldanha SA; Chase P; Eggler A; Dawson ES; Baez-Santos YM; Tomar S; Mielech AM; Baker SC; Lindsley CW; Hodder P; Mesecar A; Stauffer SR J Med Chem; 2013 Jan; 56(2):534-46. PubMed ID: 23231439 [TBL] [Abstract][Full Text] [Related]
3. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of SARS-CoV 3CL protease by flavonoids. Jo S; Kim S; Shin DH; Kim MS J Enzyme Inhib Med Chem; 2020 Dec; 35(1):145-151. PubMed ID: 31724441 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. Ghosh AK; Xi K; Ratia K; Santarsiero BD; Fu W; Harcourt BH; Rota PA; Baker SC; Johnson ME; Mesecar AD J Med Chem; 2005 Nov; 48(22):6767-71. PubMed ID: 16250632 [TBL] [Abstract][Full Text] [Related]
6. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors. Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS). Kesel AJ Curr Med Chem; 2005; 12(18):2095-162. PubMed ID: 16101496 [TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors. Zhang GN; Zhao J; Li Q; Wang M; Zhu M; Wang J; Cen S; Wang Y Eur J Med Chem; 2021 Nov; 223():113622. PubMed ID: 34147744 [TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum coronavirus antiviral drug discovery. Totura AL; Bavari S Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247 [TBL] [Abstract][Full Text] [Related]
10. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Kao RY; Tsui WH; Lee TS; Tanner JA; Watt RM; Huang JD; Hu L; Chen G; Chen Z; Zhang L; He T; Chan KH; Tse H; To AP; Ng LW; Wong BC; Tsoi HW; Yang D; Ho DD; Yuen KY Chem Biol; 2004 Sep; 11(9):1293-9. PubMed ID: 15380189 [TBL] [Abstract][Full Text] [Related]
12. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Báez-Santos YM; St John SE; Mesecar AD Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382 [TBL] [Abstract][Full Text] [Related]
13. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598 [TBL] [Abstract][Full Text] [Related]
14. Potential antivirals and antiviral strategies against SARS coronavirus infections. De Clercq E Expert Rev Anti Infect Ther; 2006 Apr; 4(2):291-302. PubMed ID: 16597209 [TBL] [Abstract][Full Text] [Related]
15. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Tong TR Infect Disord Drug Targets; 2009 Apr; 9(2):223-45. PubMed ID: 19275708 [TBL] [Abstract][Full Text] [Related]
16. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata. Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958 [TBL] [Abstract][Full Text] [Related]
18. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R Science; 2003 Jun; 300(5626):1763-7. PubMed ID: 12746549 [TBL] [Abstract][Full Text] [Related]
19. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS. Mishra J; Prasun C; Sahoo PK; Nair MS Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095 [TBL] [Abstract][Full Text] [Related]